Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis
Both denosumab and bisphosphonates are effective in preventing femoral periprosthetic bone loss following THA. Denosumab was the most efficient agent for increasing BMD at 6 months post-THA, while alendronate combined with alfacalcidol or feriparatide was most efficient at 12 months and 24 months. More high-quality direct comparisons and long-term follow-up studies are needed to determine the optimal drug and dosage for THA patients.
Authors
- Zhihu Zhao (ORCID: https://orcid.org/0000-0001-7081-8914)
- Ling Tao (ORCID: https://orcid.org/0000-0002-7076-1185)
- Wei Luo (ORCID: https://orcid.org/0009-0002-0507-8424)
- Xinlong Ma (ORCID: https://orcid.org/0009-0008-2649-6346)
- Jianxiong Ma (ORCID: https://orcid.org/0000-0001-6346-6316)
- Songqing Ye
Institutions
- Tianjin Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.3389/fphar.2025.1566890
- Citations
- 1
- Primary Topic
- Orthopaedic implants and arthroplasty
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- National Natural Science Foundation of China
- Tianjin Municipal Science and Technology Bureau